PTC Therapeutics, Inc. (PTCT)
64.30
+1.74
(+2.78%)
USD |
NASDAQ |
Oct 09, 15:21
PTC Therapeutics EPS Diluted (Quarterly) : 0.9178 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.9178 |
| March 31, 2026 | -0.034 |
| December 31, 2025 | -1.673 |
| September 30, 2025 | 0.195 |
| June 30, 2025 | -0.8298 |
| March 31, 2025 | 10.04 |
| December 31, 2024 | -0.8534 |
| September 30, 2024 | -1.386 |
| June 30, 2024 | -1.293 |
| March 31, 2024 | -1.197 |
| December 31, 2023 | -2.063 |
| September 30, 2023 | -1.764 |
| June 30, 2023 | -2.661 |
| March 31, 2023 | -1.885 |
| December 31, 2022 | -2.352 |
| September 30, 2022 | -1.526 |
| June 30, 2022 | -2.131 |
| March 31, 2022 | -1.780 |
| December 31, 2021 | -2.027 |
| September 30, 2021 | -1.893 |
| June 30, 2021 | -1.681 |
| March 31, 2021 | -1.833 |
| December 31, 2020 | -1.079 |
| September 30, 2020 | -1.030 |
| June 30, 2020 | -2.785 |
| Date | Value |
|---|---|
| March 31, 2020 | -1.806 |
| December 31, 2019 | -1.373 |
| September 30, 2019 | -1.063 |
| June 30, 2019 | -0.7474 |
| March 31, 2019 | -1.291 |
| December 31, 2018 | -0.9602 |
| September 30, 2018 | -1.060 |
| June 30, 2018 | -0.2063 |
| March 31, 2018 | -0.4628 |
| December 31, 2017 | 0.0303 |
| September 30, 2017 | -0.817 |
| June 30, 2017 | -0.441 |
| March 31, 2017 | -0.847 |
| December 31, 2016 | -0.78 |
| September 30, 2016 | -1.03 |
| June 30, 2016 | -1.14 |
| March 31, 2016 | -1.22 |
| December 31, 2015 | -1.50 |
| September 30, 2015 | -1.27 |
| June 30, 2015 | -1.14 |
| March 31, 2015 | -1.15 |
| December 31, 2014 | -0.84 |
| September 30, 2014 | -0.93 |
| June 30, 2014 | -0.86 |
| March 31, 2014 | -0.58 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Biogen, Inc. | 0.6557 |
| BioMarin Pharmaceutical, Inc. | 0.2302 |
| Arcturus Therapeutics Holdings, Inc. | -0.8368 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 83.50M |
| Revenue (Quarterly) | 360.52M |
| Total Expenses (Quarterly) | 277.02M |
| Enterprise Value | 3.680B |
| Gross Profit Margin (Quarterly) | 91.19% |
| Profit Margin (Quarterly) | 23.16% |
| Earnings Yield | -0.92% |
| Operating Earnings Yield | 2.12% |
| Normalized Earnings Yield | -1.044 |